BioSpace News Archive

Q32 Bio Announces Closing of Merger with Homology Medicines

Metacrine is a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal (GI) diseases.

Almost every factor that affects health – from genetics and the microbiome to disease and lifestyle – exerts its influence by altering metabolite levels in the body or other biological system. By producing the most accurate and comprehensive picture of the collection of metabolites, known as the metabolome, from a single biological sample, Metabolon can deliver an instantaneous snapshot of the entire physiology of a living being at a discreet point in time, as well as identify changes in that system brought about the impact of disease, medical intervention, diet or the environment.

Neuronascent (NNI) is a small corporation, that we believe has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options.

A global Contract Research Organization (CRO) with over 30 years of experience, CMIC’s skilled researchers provide cutting-edge expertise in small and large molecule bioanalysis to optimize drug development for pharmaceutical companies.

Precision BioSciences, Inc. is a pre-clinical stage gene editing company developing in vivo gene editing with its highly precise and versatile ARCUS genome editing platform.

CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology.

X-Chem is your preferred partner for innovative small molecule discovery. Synergizing DNA-encoded chemical library technology, discovery chemistry, and artificial intelligence, we provide pharmaceutical and biotech companies complete, seamless solutions for challenging, high-value therapeutic targets.

Lumos Pharma is a clinical-stage biopharmaceutical company whose mission is to develop new therapies for people with rare diseases, prioritizing its focus where the medical need is high, and the pathophysiology is clear.

Scioderm, Inc. was acquired by Amicus Therapeutics, Inc. in September of 2015. Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare genetic diseases.